Category - Developments

Developments

Roth Capital acquires MKM Partners

Roth Capital Partners completed its acquisition of MKM Partners on Jan. 31, and the combined organization will conduct business as ROTH MKM. This is the first acquisition ROTH has made in its 30-plus years of business...

February 1, 2023

Developments

First Wave to initiate Phase 2 trial of enhanced adrulipase formulation

First Wave BioPharma (NASDAQ:FWBI) plans to initiate a Phase 2 clinical trial of an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency (EPI) in...

January 31, 2023

Developments

Reneo receives FDA fast track for of long-chain fatty acid oxidation disorder

The FDA granted Reneo Pharmaceuticals’ (NASDAQ:RPHM) mavodelpar (REN001) fast track designation for long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, one of the predominant genotypes in patients with long...

January 31, 2023

Developments

Theralase to present Phase 2 NMIBC interim data at ASCO GU cancer symposium

Interim data from Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) Phase 2 non-muscle invasive bladder cancer (NMIBC) clinical study has been accepted by the American Society of Clinical Oncology (ASCO) Genito Urinary...

January 25, 2023

Developments

Precigen posts positive Phase 1 AdenoVerse data in RRP

Precigen (NASDAQ:PGEN) reported positive Phase 1 dose escalation and expansion cohort data as of the Jan. 12, 2023 cut-off for its investigational PRGN-2012 off-the-shelf AdenoVerse immunotherapy in patients with...

January 25, 2023

Developments

CMS sets national pricing for BioStem’s VENDAJE

The Center for Medicare Services (CMS) established national pricing for BioStem Technologies’ (OTCQB:BSEM) VENDAJE in all Medicare Administrative Contractors (MAC) regions, effective Jan. 1, 2023. VENDAJE allografts now...

January 24, 2023

Developments

IntelGenx, ARWAN Pharma in supply agreement for RIZAPORT in MENA countries

IntelGenx (TSX:IGX; OTCQB:IGXT) entered into an exclusive supply agreement for its RIZAPORT product with ARWAN Pharmaceuticals Industries Lebanon for various countries in the Middle East and North Africa, known as the...

January 23, 2023

Developments

Jazz, Zymeworks post positive Phase 2 survival in metastatic gastroesophageal adenocarcinoma

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Zymeworks (NASDAQ:ZYME) reported the first overall survival (OS) data from a Phase 2 trial examining zanidatamab, an investigational HER2-targeted bispecific antibody, in...

January 19, 2023

Developments

Hepion posts positive preclinical results in multiple myeloma expanding rencofilstat’s anti-cancer potential

Hepion Pharmaceuticals (NASDAQ:HEPA) announced positive results of preclinical studies examining rencofilstat as a potential therapeutic for multiple myeloma (MM). Rencofilstat exerted anti-cancer activity across a...

January 18, 2023

Developments

FDA grants Avidity fast tract for facioscapulohumeral muscular dystrophy

The FDA granted Avidity Biosciences (NASDAQ:RNA) fast track designation to the company’s AOC 1020 drug candidate for the treatment of facioscapulohumeral muscular dystrophy (FSHD). FSHD is a serious, rare, hereditary...

January 18, 2023

Category - Developments

Subscribe